New
HealthMore in Health→
Opinion Essay Faults FDA Nominee Heidi Overton on Mifepristone Science
Key Takeaways
- STAT published a First Opinion essay on September 25, 2026, arguing FDA commissioner nominee Heidi Overton is ignoring the science on mifepristone.
- The column was written by Julie F. Kay, founder and CEO of Reproductive Futures.
- Kay's essay says the appointment leaves mifepristone with "a new boss but an old problem."
- The piece is advocacy rather than reporting and frames the confirmation hearing as a test of the nominee's willingness to engage with drug evidence.
DE
DT Editorial Team··via statnews.com